ClinicalTrials.gg
CompletedNCT02825251Onset® 5Updated Nov 21, 2019Results posted

Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes

A Phase 3 interventional study of Faster-acting insulin aspart and insulin aspart in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 92 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-21.

Primary conditionDiabetes Mellitus, Type 1Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 1
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 1, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
472
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1 — 2 open to participants now, 2 under way, none of them phase 3. Insulin Aspart · Diabetes Mellitus, Type 1.

Enrollment
10th of 87
472 · median 50
Started
2016
with 4 others
Phase 3
24 of 87
none open now
Registered
65th of 87
by date
Lead sponsor
55 of 87
Novo Nordisk A/S

Among the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1, this one is the 10th largest by enrollment, is one of 5 that started in 2016, is one of 24 in phase 3, and was the 65th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Insulin Aspart

Insulin Aspart: first FDA approval 2000 (NOVOLOG PENFILL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to investigate efficacy and safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart compared to NovoRapid® in Adults with Type 1 Diabetes.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1

Browse trials for

04

In context

Diabetes Mellitus, Type 1 Reclassified

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's enrollment of 472 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, age at least 18 years at the time of signing the
  • Diagnosed with T1DM (Type 1 Diabetes Mellitus) (based on clinical judgement and/or supported by laboratory analysis as per local guidelines) equal or above 1 year prior to the day of screening
  • Using the same Medtronic pump (Minimed 530G (551/751), Paradigm Veo (554/754), Paradigm Revel (523/723), Paradigm (522/722)) for CSII in a basal-bolus regimen with a rapid acting insulin analogue for at least six months prior to screening and willing to stay on the same pump model throughout the trial (if the model is changed the change should not exceed 7 consecutive days.)
  • (glycosylated ) 7.0-9.0% (53-75 mmol/mol) as assessed by central laboratory at screening
  • (BMI) below or equal to 35.0 kg/m\^2 at screening
  • Ability and willingness to take at least 3 daily meal-time insulin bolus infusions every day throughout the trial

Exclusion criteria

Exclusion Criteria:

  • Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or within the past 180 days prior to the day of screening
  • Planned coronary, carotid or peripheral artery revascularisation known on the day of screening
  • History of hospitalization for ketoacidosis below or equal to 180 days prior to the day of screening
  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 days before screening
  • Any condition which, in the opinion of the Investigator, might jeopardise a Subject's safety or compliance with the protocol
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
472 participants (actual)

Study arms

  • Experimental
    Faster-acting insulin aspart CSII

    Drug: Faster-acting insulin aspart

  • Active comparator
    NovoRapid® CSII

    Drug: insulin aspart

Interventions

07

What researchers measure

Primary outcomes

  1. Change in Glycosylated Haemoglobin (HbA1c)

    Change from baseline (week 0) in HbA1c was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In-trial period: the observation period from date of randomisation until last trial-related subject-site contact.

    Time frame: Week 0, week 16

Secondary outcomes

  1. Change From Baseline in 1-hour PPG Increment

    Change from baseline (week 0) in 1-hour postprandial glucose (PPG) increment was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, Week 16

  2. Change From Baseline in 1,5-anhydroglucitol

    Change from baseline (week 0) in 1,5-anhydroglucitol was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, Week 16

  3. Change From Baseline in Time Spent in Low IG (≤3.9 mmol/L [70 mg/dL]) During CGM

    Change from baseline (week 0) in low interstitial glucose (IG) (≤3.9 mmol/L \[70 mg/dL\]) during continuous glucose monitoring (CGM) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 16

  4. Change From Baseline in Fasting Plasma Glucose (FPG)

    Change from baseline (week 0) in FPG was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 16

  5. Percentage of Subjects Reaching HbA1c <7.0% (53 mmol/Mol)

    Percentage of subjects reaching HbA1c \<7.0% (53 mmol/mol) was evaluated after 16 weeks of randomisation. Subjects without an HbA1c measurement at week 16 were considered not to have achieved HbA1c target at week 16. The results are based on the in-trial period.

    Time frame: Week 16

  6. Percentage of Subjects Reaching HbA1c <7.0% (53 mmol/Mol) Without Severe Hypoglycaemic Episodes

    Percentage of subjects reaching HbA1c \<7.0% (53 mmol/mol) without treatment emergent severe hypoglycaemic episodes was evaluated after 16 weeks of randomisation. Subjects without an HbA1c measurement at week 16 were considered not to have achieved HbA1c target at week 16. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose (PG) concentrations may not be available during an event, but neurological recovery following the return of PG to normal was considered sufficient evidence that the event was induced by a low PG concentration. Treatment emergent: hypoglycaemic episodes were defined as treatment emergent if the onset of the episode occurred on or after the first day of IMP administration after randomisation (in week 0) and no later than one day after the last day on IMP (i.e., maximum week 16 + 1 day). The results are based on the in-trial period.

    Time frame: Week 16

  7. Change From Baseline in 30-min, 1-hour, 2-hour, 3-hour and 4-hour PPG (Meal Test)

    Change from baseline (week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour postprandial glucose (PPG \[meal test\]) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. Meal test: The subjects were given a carbohydrate-rich standardised liquid meal immediately after bolus (faster aspart or NovoRapid®) infusion in the morning of the meal test. The subjects were to consume the meal as quickly as possible (within 12 minutes) and blood samples were drawn after 30 minutes, 1, 2, 3 and 4 hours from the start of the meal.

    Time frame: Week 0, week 16

  8. Change From Baseline in 30-min, 2-hour, 3-hour and 4-hour PPG Increment (Meal Test)

    Change from baseline (week 0) in 30-min, 2-hour, 3-hour and 4-hour PPG increment (meal test) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. Meal test: The subjects were given a carbohydrate-rich standardised liquid meal immediately after bolus (faster aspart or NovoRapid®) infusion in the morning of the meal test. The subjects were to consume the meal as quickly as possible (within 12 minutes) and PPG was evaluated after 30 minutes, 1, 2, 3 and 4 hours from the start of the meal.

    Time frame: Week 0, week 16

  9. Change From Baseline in Mean of the 7-7-9 Point Self-measured Plasma Glucose (SMPG) Profile

    Change from baseline (week 0) in mean of the 7-7-9 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. 7-7-9 point SMPG was measured at the following mentioned time points: 1) Before breakfast, 2) 60 mins after the start of Breakfast, 3) Before lunch, 4) 60 mins after the start of lunch, 5) Before main evening meal, 6) 60 mins after the start of main evening meal, 7) At bedtime, 8) At 4 AM, 9) Before breakfast.

    Time frame: Week 0, week 16

  10. Change From Baseline of the 7-7-9 Point SMPG Profile: PPG (Mean, Breakfast, Lunch and Main Evening Meal)

    Change from baseline (week 0) in PPG (breakfast, lunch, main evening meal and mean over all meals) of the 7-7-9 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 16

  11. Change From Baseline of the 7-7-9 Point SMPG Profile: PPG Increment (Mean, Breakfast, Lunch and Main Evening Meal)

    Change from baseline (week 0) in PPG increment (breakfast, lunch, main evening meal and mean over all meals) of the 7-7-9 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 16

  12. Change From Baseline of the 7-7-9 Point SMPG Profile: Pre-prandial Plasma Glucose (PG) (Mean, Pre-breakfast, Pre-lunch, Pre-main Evening Meal)

    Change from baseline (week 0) in pre-prandial PG (pre-breakfast, pre-lunch, pre-main evening meal and mean over all meals) of the 7-7-9 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 16

  13. Change From Baseline of the 7-7-9 Point SMPG Profile: Fluctuation in 7-7-9 Point Profile

    Fluctuation in 7-point SMPG profile was the average absolute difference from the mean of the SMPG profile. Reported results are fluctuation in the 7-7-9 point SMPG profile at baseline (week 0) and after 16 weeks of randomisation (i.e., week 16). The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 16

  14. Change From Baseline of the 7-7-9 Point SMPG Profile: in Nocturnal SMPG Measurements

    Change from baseline (week 0) in nocturnal SMPG measurements was assessed by considering the differences between PG values available at bedtime, at 4 AM and the before breakfast value the following day: (4 AM PG value minus at bedtime PG value), (before breakfast PG value minus at bedtime PG value) and (before breakfast PG value minus 4 AM PG value). Change from baseline in nocturnal increments in SMPG measurements of the 7-7-9 point SMPG profile was evaluated after 16 weeks of randomisation and presented during three different time intervals as follows: 1) 04:00 to breakfast, 2) bedtime to 04:00, and 3) bedtime to breakfast. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 16

  15. Percentage of Subjects Reaching Overall PPG (1 Hour) ≤7.8 mmol/L [140 mg/dL]

    Percentage of subjects reaching overall PPG (1 hour) ≤7.8 mmol/L \[140 mg/dL\] was evaluated after 16 weeks of randomisation. Subjects without a postprandial glucose measurement at week 16 were considered not to have achieved HbA1c target at week 16. The results are based on the in-trial period.

    Time frame: Week 16

  16. Percentage of Subjects Reaching Overall PPG (1 Hour) ≤7.8 mmol/L [140 mg/dL] Without Severe Hypoglycaemia

    Percentage of subjects reaching overall PPG (1 hour) ≤7.8 mmol/L \[140 mg/dL\] without treatment emergent severe hypoglycaemia was evaluated after 16 weeks of randomisation. Subjects without a postprandial glucose measurement at week 16 were considered not to have achieved HbA1c target at week 16. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose (PG) concentrations may not be available during an event, but neurological recovery following the return of PG to normal was considered sufficient evidence that the event was induced by a low PG concentration. The results are based on the in-trial period.

    Time frame: Week 16

  17. Change From Baseline in Lipids-lipoproteins Profile (Total Cholesterol, High Density Lipoproteins, Low Density Lipoproteins)

    Reported results are lipids-lipoproteins (total cholesterol, high density lipoproteins, low density lipoproteins) values at baseline (week 0) and after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 16

  18. Insulin Dose in Units/Day: Total Basal

    Total basal insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period: the observation period from date of first dose of randomised trial products (faster aspart and NovoRapid®) to no later than 7 days after the day of last dose of randomised trial products.

    Time frame: Week 16

  19. Insulin Dose in Units/Day: Total Bolus

    Total bolus insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 16

  20. Insulin Dose in Units/Day: Total Daily Insulin Dose

    Total insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 16

  21. Insulin Dose in Units/Day: Individual Meal Insulin Dose

    No data was collected for individual meal insulin dose.

    Time frame: Week 16

  22. Insulin Dose in Units/kg/Day: Total Basal

    Total basal insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 16

  23. Insulin Dose in Units/kg/Day: Total Bolus

    Total bolus insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 16

  24. Insulin Dose in Units/kg/Day: Total Daily Insulin Dose

    Total insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 16

  25. Insulin Dose in Units/kg/Day: Individual Meal Insulin Dose

    No data was collected for individual meal insulin dose.

    Time frame: Week 16

  26. Insulin Delivery Pump Parameter: Insulin Carbohydrate Ratio

    Insulin carbohydrate ratio was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 16

  27. Insulin Delivery Pump Parameter: Glucose Sensitivity Factor

    Glucose sensitivity factor was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 16

  28. Insulin Delivery Pump Parameter: Active Insulin Time

    Active insulin time was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 16

  29. Change From Baseline in Mean IG Increment (0-30 Min, 0-1 Hour and 0-2 Hours After Start of Meal) (Mean, Breakfast, Lunch and Main Evening Meal)

    Change from baseline (week 0) in mean interstitial glucose (IG) increment (0-30 minutes (min), 0-1 hour (h) and 0-2 h after start of meal) (breakfast, lunch, main evening meal and mean across all meals) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 16

  30. Change From Baseline in Mean Time to the IG Peak After Start of Meal (Mean, Breakfast, Lunch and Main Evening Meal)

    Change from baseline (week 0) in mean time to the IG peak after start of meal (breakfast, lunch, main evening meal and mean across all meals) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 16

  31. Change From Baseline in Mean IG Peak After Start of Meal (Mean, Breakfast, Lunch and Main Evening Meal)

    Change from baseline (week 0) in mean IG peak after start of meal (breakfast, lunch, main evening meal and mean across all meals) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 16

  32. Percentage of Time Spent With IG ≤2.5, 3.0, 3.5, 3.9 mmol/L [45, 54, 63, 70 mg/dL]) and IG >10.0, 12.0, 13.9 mmol/L [180, 216, 250 mg/dL])

    Percentage of time spent with IG ≤2.5, 3.0, 3.5, 3.9 mmol/L \[45, 54, 63, 70 mg/dL\]) and IG \>10.0, 12.0, 13.9 mmol/L \[180, 216, 250 mg/dL\]) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 16

  33. Incidence of Episodes With IG ≤2.5, 3.0, 3.5, 3.9 mmol/L [45, 54, 63, 70 mg/dL]) and IG >10.0, 12.0, 13.9 mmol/L [180, 216, 250 mg/dL])

    Incidence of episodes with IG ≤2.5, 3.0, 3.5, 3.9 mmol/L \[45, 54, 63, 70 mg/dL\]) and IG \>10.0, 12.0, 13.9 mmol/L \[180, 216, 250 mg/dL\]) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 16

  34. Change From Baseline in Mean of the IG Profile

    Change from baseline (week 0) in mean of the IG profile was evaluated after 16 weeks of randomisation. The mean of an IG profile is defined as the time integral of the profile over the profile's length, divided by the profile's length. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 16

  35. Percentage of Time Spent Within IG Target Range 4.0-7.8 mmol/L (71-140 mg/dL) and 4.0-10 mmol/L (71-180 mg/dL)

    Percentage of time spent within IG target range 4.0-7.8 mmol/L (71-140 mg/dL) and 4.0-10 mmol/L (71-180 mg/dL) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 16

  36. Variation in the IG Profile

    Variation in IG profile was the average absolute difference from the mean of the IG profile. Variation in the IG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 16

  37. Area Under the Curve (AUC3.9-IG) for IG ≤3.9 mmol/L [70 mg/dL]

    Area under the curve (AUC3.9-IG) for IG ≤3.9 mmol/L \[70 mg/dL\] was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 16

  38. Change From Baseline in AUCIG,0-15min

    Change from baseline (week 0) in area under the curve for interstitial glucose (AUCIG),0-15 minutes during meal test was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 16

  39. Change From Baseline in AUCIG,0-30min

    Change from baseline (week 0) in AUCIG,0-30 minutes during meal test was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 16

  40. Change From Baseline in AUCIG,0-1h

    Change from baseline (week 0) in AUCIG,0-1 hour during meal test was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 16

  41. Change From Baseline in AUCIG,0-2h

    Change from baseline (week 0) in AUCIG,0-2 hours during meal test was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 16

  42. Change From Baseline in AUCIG,0-4h

    Change from baseline (week 0) in AUCIG,0-24hours during meal test was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 16

  43. Change From Baseline in Time to the IG Peak After Start of Meal

    Change from baseline (week 0) in time to the IG peak after start of meal-test meal was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 16

  44. Change From Baseline in IG Peak After Start of Meal

    Change from baseline (week 0) in IG peak after start of meal-test meal was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 16

  45. Number of Treatment Emergent Adverse Events (AEs)

    Treatment emergent adverse events (TEAEs) were recorded from week 0 to week 16. A TEAE was defined as an event that has an onset date on or after the first day of exposure to randomised treatment (in week 0), and no later than seven days after the last day of randomised treatment (i.e., maximum week 16 + 7 days). The results are based on the on-treatment period.

    Time frame: Weeks 0-16

  46. Number of Treatment Emergent Infusion Site Reactions

    Number of treatment emergent infusion site reactions were recorded from week 0 to week 16. The results are based on the on-treatment period.

    Time frame: Weeks 0-16

  47. Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association (ADA) and Novo Nordisk (NN) Definition: Overall

    ADA classification of hypo: 1. Severe: Requiring assistance of another person to actively administer carbohydrate/glucagon/take other corrective actions. PG levels may not be available during an event, but neurological recovery following return of PG to normal is considered sufficient evidence that event was induced by a low PG level. 2. Documented symptomatic: PG ≤3.9 mmol/L with symptoms. 3. Asymptomatic: PG ≤3.9 mmol/L without symptoms. 4. Probable symptomatic: No measurement with symptoms. 5. Pseudo: PG \>3.9 mmol/L with symptoms. 6. Unclassifiable. NN classification of hypo: 1. BG confirmed: PG \<3.1 mmol/L with/without symptoms. 2. Severe or BG confirmed symptomatic: Severe as per ADA and BG confirmed by PG \<3.1 mmol/L with symptoms. 3. Severe or BG confirmed: Severe as per ADA and BG confirmed by PG \<3.1 mmol/L with/without symptoms. 4. Unclassifiable. Not able to self treat-unclassifiable: Not able to self treat but not classifiable as severe hypo.

    Time frame: Weeks 0-16

  48. Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Daytime Hypoglycaemic Episodes (06:00-00:00 - Inclusive)

    Number of treatment emergent day time hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 06:00 and 00:00 (both included). The results are based on the on-treatment period.

    Time frame: Weeks 0-16

  49. Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Nocturnal Hypoglycaemic Episodes (00:01-05:59 - Inclusive)

    Number of treatment emergent nocturnal hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 00:01 and 05:59 (both included). The results are based on the on-treatment period.

    Time frame: Weeks 0-16

  50. Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 1 Hour After Start of the Meal

    Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 1 hour after start of the meal. The results are based on the on-treatment period.

    Time frame: Weeks 0-16

  51. Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes During First 2 Hours After Start of the Meal

    Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 2 hours after start of the meal. The results are based on the on-treatment period.

    Time frame: Weeks 0-16

  52. Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes During First 4 Hours After Start of the Meal

    Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 4 hours after start of the meal. The results are based on the on-treatment period.

    Time frame: Weeks 0-16

  53. Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes Occurring Between 2 to 4 Hours After Start of the Meal

    Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 2 to 4 hours after start of the meal. The results are based on the on-treatment period.

    Time frame: Weeks 0-16

  54. Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes Occurring Between 1 Hour to 2 Hours After Start of the Meal

    Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 1 hour to 2 hours after start of the meal. The results are based on the on-treatment period.

    Time frame: Weeks 0-16

  55. Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes Occurring Between 2 to 3 Hours After Start of the Meal

    Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 2 to 3 hours after start of the meal. The results are based on the on-treatment period.

    Time frame: Weeks 0-16

  56. Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes Occurring Between 3 to 4 Hours After Start of the Meal

    Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 3 to 4 hours after start of the meal. The results are based on the on-treatment period.

    Time frame: Weeks 0-16

  57. Number of Unexplained Episodes of Hyperglycaemia (Confirmed by SMPG)

    Unexplained hyperglycaemia was defined as a confirmed PG value ≥16.7 mmol/L (300 mg/dL) and was unexplained (i.e. no apparent medical, dietary, insulin dosage or pump failure reason). The results are based on the on-treatment period.

    Time frame: Weeks 0-16

  58. Change From Baseline in Physical Examination: Respiratory System

    Reported results are respiratory system-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  59. Change From Baseline in Physical Examination: Cardiovascular System

    Reported results are cardiovascular system-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  60. Change From Baseline in Physical Examination: Central and Peripheral Nervous System

    Reported results are central and peripheral nervous system-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  61. Change From Baseline in Physical Examination: Gastrointestinal System, Including the Mouth

    Reported results are gastrointestinal system-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  62. Change From Baseline in Physical Examination: Musculoskeletal System

    Reported results are musculoskeletal system-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  63. Change From Baseline in Physical Examination: Skin

    Reported results are skin-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  64. Change From Baseline in Physical Examination: Head, Ears, Eyes, Nose, Throat and Neck

    Reported results are head, ears, eyes, nose, throat and neck-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  65. Change From Baseline in Vital Sign: Blood Pressure

    Change from baseline (week 0) in blood pressure (both systolic and diastolic) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  66. Change From Baseline in Vital Sign: Pulse

    Change from baseline (week 0) in pulse was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  67. Change From Screening in Electrocardiogram (ECG)

    Reported results are ECG findings at screening (week -6) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  68. Change From Screening in Fundus Photography/Fundoscopy

    Reported results are fundus photography/fundoscopy (for both left and right eye) findings at screening (week -6) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) AAbnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  69. Change From Baseline in Haematology: Haemoglobin

    Change from baseline (week 0) in haemoglobin was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  70. Change From Baseline in Haematology: Haematocrit

    Change from baseline (week 0) in haematocrit was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  71. Change From Baseline in Haematology: Erythrocytes

    Change from baseline (week 0) in erythrocytes was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  72. Change From Baseline in Haematology: Thrombocytes

    Change from baseline (week 0) in thrombocytes was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  73. Change From Baseline in Haematology: Leucocytes

    Change from baseline (week 0) in leucocytes was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  74. Change From Baseline in Biochemistry: Total Protein

    Change from baseline (week 0) in total protein was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  75. Change From Baseline in Biochemistry: Creatinine

    Change from baseline (week 0) in creatinine was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  76. Change From Baseline in Biochemistry: Alanine Aminotransferase (ALT)

    Change from baseline (week 0) in ALT was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  77. Change From Baseline in Biochemistry: Aspartate Aminotransferase (AST)

    Change from baseline (week 0) in AST was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  78. Change From Baseline in Biochemistry: Alkaline Phosphatase (ALP)

    Change from baseline (week 0) in ALP was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  79. Change From Baseline in Biochemistry: Sodium

    Change from baseline (week 0) in sodium was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  80. Change From Baseline in Biochemistry: Potassium

    Change from baseline (week 0) in potassium was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  81. Change From Baseline in Biochemistry: Albumin

    Change from baseline (week 0) in albumin was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  82. Change From Baseline in Biochemistry: Total Bilirubin

    Change from baseline (week 0) in bilirubin was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  83. Change From Baseline in Urinalysis: Albumin/Creatine Ratio

    Change from baseline (week 0) in albumin/creatine ratio was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  84. Change From Baseline in Urinalysis: Erythrocytes

    Reported results are urine erythrocytes-test findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: a) Negative, b) Trace, c) 1+, d) 2+ and e) 3+. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  85. Change From Baseline in Urinalysis: Protein

    Reported results are urine protein-test findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: a) Negative, b) Trace, c) 1+, d) 2+ e) 3+ and f) 4+. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  86. Change From Baseline in Urinalysis: Ketones

    Reported results are urine ketone-test findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: a) Negative, b) Trace, c) 1+, d) 2+ e) 3+ and f) 4+. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  87. Change From Baseline in Body Weight

    Change from baseline (week 0) in body weight was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  88. Change From Baseline in Body Mass Index (BMI)

    Change from baseline (week 0) in BMI was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 16

  89. Number of Change-of-infusion-sets Per Week

    Number of change-of-infusion-sets per week was evaluated from week 0 to week 16. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0-16

  90. Number of Subjects With at Least One Non-routine Change-of-infusion-sets Categorised by Reasons for Change-of-infusion-sets

    Number of subjects with at least one non-routine change-of-infusion-sets categorised by reasons for change-of-infusion-sets was evaluated from week 0 to week 16. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. Reasons for change-of-infusion-sets are categorised as follows: Category-1: A perceived occlusion by the subject Category-2: Any problems related to the infusion set Category-3: Any technical issues with the pump Category-4: Changes in the insulin solution in the infusion set or reservoir Category-5: High BG with no other explanation which made the subject change the infusion set Category-6: Infusion site reaction Category-7: Missing

    Time frame: Week 0-16

08

Results

Posted Jul 24, 2018

Participant flow

The trial was conducted at 92 sites in 9 countries.as follows: Belgium (7), Canada (8), France (10), Germany (9), Netherlands (9), Russian Federation (11), Slovenia (2), United Kingdom (6), and United States (30). One (1) site in the Netherlands screened, but didn't randomise any subject.

Participant flow — Overall Study
MilestoneFaster AspartNovoRapid
Started236236
Completed233230
Not completed36
Withdrew: Adverse event01
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject14
Withdrew: Unclassified20

Outcome measures

PrimaryChange in Glycosylated Haemoglobin (HbA1c)

Change from baseline (week 0) in HbA1c was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In-trial period: the observation period from date of randomisation until last trial-related subject-site contact.

Time frame:
Week 0, week 16
Reported as:
Mean · Percentage (%) of HbA1c
Change in Glycosylated Haemoglobin (HbA1c)
Percentage (%) of HbA1cFaster AspartNovoRapid
Baseline7.49 ± 0.557.49 ± 0.53
Change from baseline-0.06 ± 0.50-0.14 ± 0.44
Statistical analysis
  • Faster Aspart vs NovoRapid · ANOVA · Treatment difference: 0.09 · 95% CI 0.01 to 0.17
SecondaryChange From Baseline in 1-hour PPG Increment

Change from baseline (week 0) in 1-hour postprandial glucose (PPG) increment was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, Week 16
Reported as:
Mean · mmol/L
Change From Baseline in 1-hour PPG Increment
mmol/LFaster AspartNovoRapid
Baseline4.67 ± 3.094.62 ± 3.00
Change from baseline-0.89 ± 3.440.05 ± 3.37
SecondaryChange From Baseline in 1,5-anhydroglucitol

Change from baseline (week 0) in 1,5-anhydroglucitol was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, Week 16
Reported as:
Mean · ug/mL
Change From Baseline in 1,5-anhydroglucitol
ug/mLFaster AspartNovoRapid
Baseline4.20 ± 2.344.13 ± 2.14
Change from baseline0.14 ± 1.480.25 ± 1.42
SecondaryChange From Baseline in Time Spent in Low IG (≤3.9 mmol/L [70 mg/dL]) During CGM

Change from baseline (week 0) in low interstitial glucose (IG) (≤3.9 mmol/L \[70 mg/dL\]) during continuous glucose monitoring (CGM) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 16
Reported as:
Mean · min/day
Change From Baseline in Time Spent in Low IG (≤3.9 mmol/L [70 mg/dL]) During CGM
min/dayFaster AspartNovoRapid
Baseline85.42 ± 65.2079.88 ± 60.46
Change from baseline-6.96 ± 55.292.85 ± 58.56
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG)

Change from baseline (week 0) in FPG was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 16
Reported as:
Mean · mmol/L
Change From Baseline in Fasting Plasma Glucose (FPG)
mmol/LFaster AspartNovoRapid
Baseline7.60 ± 2.647.40 ± 2.31
Change from baseline-0.03 ± 3.190.25 ± 3.05
SecondaryPercentage of Subjects Reaching HbA1c <7.0% (53 mmol/Mol)

Percentage of subjects reaching HbA1c \<7.0% (53 mmol/mol) was evaluated after 16 weeks of randomisation. Subjects without an HbA1c measurement at week 16 were considered not to have achieved HbA1c target at week 16. The results are based on the in-trial period.

Time frame:
Week 16
Reported as:
Number · % of subjects
Percentage of Subjects Reaching HbA1c <7.0% (53 mmol/Mol)
% of subjectsFaster AspartNovoRapid
Percentage of Subjects Reaching HbA1c <7.0% (53 mmol/Mol)20.323.3
SecondaryPercentage of Subjects Reaching HbA1c <7.0% (53 mmol/Mol) Without Severe Hypoglycaemic Episodes

Percentage of subjects reaching HbA1c \<7.0% (53 mmol/mol) without treatment emergent severe hypoglycaemic episodes was evaluated after 16 weeks of randomisation. Subjects without an HbA1c measurement at week 16 were considered not to have achieved HbA1c target at week 16. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose (PG) concentrations may not be available during an event, but neurological recovery following the return of PG to normal was considered sufficient evidence that the event was induced by a low PG concentration. Treatment emergent: hypoglycaemic episodes were defined as treatment emergent if the onset of the episode occurred on or after the first day of IMP administration after randomisation (in week 0) and no later than one day after the last day on IMP (i.e., maximum week 16 + 1 day). The results are based on the in-trial period.

Time frame:
Week 16
Reported as:
Number · % of subjects
Percentage of Subjects Reaching HbA1c <7.0% (53 mmol/Mol) Without Severe Hypoglycaemic Episodes
% of subjectsFaster AspartNovoRapid
Percentage of Subjects Reaching HbA1c <7.0% (53 mmol/Mol) Without Severe Hypoglycaemic Episodes18.622.5
SecondaryChange From Baseline in 30-min, 1-hour, 2-hour, 3-hour and 4-hour PPG (Meal Test)

Change from baseline (week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour postprandial glucose (PPG \[meal test\]) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. Meal test: The subjects were given a carbohydrate-rich standardised liquid meal immediately after bolus (faster aspart or NovoRapid®) infusion in the morning of the meal test. The subjects were to consume the meal as quickly as possible (within 12 minutes) and blood samples were drawn after 30 minutes, 1, 2, 3 and 4 hours from the start of the meal.

Time frame:
Week 0, week 16
Reported as:
Mean · mmol/L
Change From Baseline in 30-min, 1-hour, 2-hour, 3-hour and 4-hour PPG (Meal Test)
mmol/LFaster AspartNovoRapid
30-min (Baseline)10.54 ± 3.3310.30 ± 2.96
1-hour (Baseline)12.18 ± 3.9611.96 ± 3.81
2-hour (Baseline)13.17 ± 4.7713.04 ± 4.35
3-hour (Baseline)11.38 ± 4.6511.48 ± 4.28
4-hour (Baseline)9.07 ± 4.319.18 ± 3.83
30-min (Change from baseline)-0.50 ± 4.050.42 ± 3.75
1-hour (Change from baseline)-0.85 ± 4.650.36 ± 4.58
2-hour (Change from baseline)-0.80 ± 5.330.42 ± 5.01
3-hour (Change from baseline)-0.33 ± 5.120.20 ± 4.75
4-hour (Change from baseline)0.00 ± 4.760.21 ± 4.10
SecondaryChange From Baseline in 30-min, 2-hour, 3-hour and 4-hour PPG Increment (Meal Test)

Change from baseline (week 0) in 30-min, 2-hour, 3-hour and 4-hour PPG increment (meal test) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. Meal test: The subjects were given a carbohydrate-rich standardised liquid meal immediately after bolus (faster aspart or NovoRapid®) infusion in the morning of the meal test. The subjects were to consume the meal as quickly as possible (within 12 minutes) and PPG was evaluated after 30 minutes, 1, 2, 3 and 4 hours from the start of the meal.

Time frame:
Week 0, week 16
Reported as:
Mean · mmol/L
Change From Baseline in 30-min, 2-hour, 3-hour and 4-hour PPG Increment (Meal Test)
mmol/LFaster AspartNovoRapid
30-min (Baseline)3.02 ± 2.162.95 ± 2.03
2-hour (Baseline)5.65 ± 4.125.70 ± 3.66
3-hour (Baseline)3.85 ± 4.324.13 ± 3.72
4-hour (Baseline)1.57 ± 4.231.83 ± 3.52
30-min (Change from baseline)-0.53 ± 2.470.11 ± 2.25
2-hour (Change from baseline)-0.82 ± 4.390.09 ± 4.13
3-hour (Change from baseline)-0.35 ± 4.53-0.14 ± 4.07
4-hour (Change from baseline)0.01 ± 4.50-0.11 ± 3.76
SecondaryChange From Baseline in Mean of the 7-7-9 Point Self-measured Plasma Glucose (SMPG) Profile

Change from baseline (week 0) in mean of the 7-7-9 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. 7-7-9 point SMPG was measured at the following mentioned time points: 1) Before breakfast, 2) 60 mins after the start of Breakfast, 3) Before lunch, 4) 60 mins after the start of lunch, 5) Before main evening meal, 6) 60 mins after the start of main evening meal, 7) At bedtime, 8) At 4 AM, 9) Before breakfast.

Time frame:
Week 0, week 16
Reported as:
Mean · mmol/L
Change From Baseline in Mean of the 7-7-9 Point Self-measured Plasma Glucose (SMPG) Profile
mmol/LFaster AspartNovoRapid
Baseline9.24 ± 1.719.10 ± 1.40
Change from baseline0.19 ± 1.910.10 ± 1.58
SecondaryChange From Baseline of the 7-7-9 Point SMPG Profile: PPG (Mean, Breakfast, Lunch and Main Evening Meal)

Change from baseline (week 0) in PPG (breakfast, lunch, main evening meal and mean over all meals) of the 7-7-9 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 16
Reported as:
Mean · mmol/L
Change From Baseline of the 7-7-9 Point SMPG Profile: PPG (Mean, Breakfast, Lunch and Main Evening Meal)
mmol/LFaster AspartNovoRapid
Breakfast (baseline)10.82 ± 2.9910.28 ± 3.07
Lunch (baseline)9.65 ± 3.059.62 ± 2.68
Main evening meal (baseline)9.79 ± 3.019.34 ± 3.06
Mean over all meals (baseline)10.07 ± 2.099.74 ± 1.99
Breakfast (Change from baseline)-0.33 ± 3.610.23 ± 3.79
Lunch (Change from baseline)0.27 ± 3.750.05 ± 3.57
Main evening meal (Change from baseline)-0.35 ± 3.810.58 ± 3.61
Mean over all meals (Change from baseline)0.06 ± 2.330.13 ± 2.21
SecondaryChange From Baseline of the 7-7-9 Point SMPG Profile: PPG Increment (Mean, Breakfast, Lunch and Main Evening Meal)

Change from baseline (week 0) in PPG increment (breakfast, lunch, main evening meal and mean over all meals) of the 7-7-9 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 16
Reported as:
Mean · mmol/L
Change From Baseline of the 7-7-9 Point SMPG Profile: PPG Increment (Mean, Breakfast, Lunch and Main Evening Meal)
mmol/LFaster AspartNovoRapid
Breakfast (baseline)2.62 ± 3.161.93 ± 3.28
Lunch (baseline)1.80 ± 2.771.77 ± 2.47
Main evening meal (baseline)1.04 ± 3.070.52 ± 2.69
Mean over all meals (baseline)1.93 ± 1.941.48 ± 1.86
Breakfast (Change from baseline)-0.75 ± 3.900.03 ± 3.67
Lunch (Change from baseline)-0.43 ± 3.25-0.27 ± 3.13
Main evening meal (Change from baseline)-0.47 ± 3.510.35 ± 3.79
Mean over all meals (Change from baseline)-0.53 ± 1.990.12 ± 1.92
SecondaryChange From Baseline of the 7-7-9 Point SMPG Profile: Pre-prandial Plasma Glucose (PG) (Mean, Pre-breakfast, Pre-lunch, Pre-main Evening Meal)

Change from baseline (week 0) in pre-prandial PG (pre-breakfast, pre-lunch, pre-main evening meal and mean over all meals) of the 7-7-9 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 16
Reported as:
Mean · mmol/L
Change From Baseline of the 7-7-9 Point SMPG Profile: Pre-prandial Plasma Glucose (PG) (Mean, Pre-breakfast, Pre-lunch, Pre-main Evening Meal)
mmol/LFaster AspartNovoRapid
Pre-breakfast (baseline)8.40 ± 2.508.31 ± 2.32
Pre-lunch (baseline)8.28 ± 2.858.21 ± 2.32
Pre-main evening meal (baseline)8.68 ± 2.768.87 ± 2.62
Pre-mean over all meals (baseline)8.39 ± 1.738.45 ± 1.54
Pre-breakfast (Change from baseline)0.36 ± 3.330.26 ± 3.05
Pre-lunch (Change from baseline)0.39 ± 3.540.21 ± 3.12
Pre-main evening meal (Change from baseline)0.15 ± 3.720.13 ± 3.18
Pre-mean over all meals (Change from baseline)0.39 ± 2.000.21 ± 1.84
SecondaryChange From Baseline of the 7-7-9 Point SMPG Profile: Fluctuation in 7-7-9 Point Profile

Fluctuation in 7-point SMPG profile was the average absolute difference from the mean of the SMPG profile. Reported results are fluctuation in the 7-7-9 point SMPG profile at baseline (week 0) and after 16 weeks of randomisation (i.e., week 16). The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 16
Reported as:
Median · mmol/L
Change From Baseline of the 7-7-9 Point SMPG Profile: Fluctuation in 7-7-9 Point Profile
mmol/LFaster AspartNovoRapid
Baseline2.14 (0.4 to 4.9)2.05 (0.9 to 4.0)
Last in-trial value2.06 (0.9 to 5.2)2.06 (0.7 to 3.8)
SecondaryChange From Baseline of the 7-7-9 Point SMPG Profile: in Nocturnal SMPG Measurements

Change from baseline (week 0) in nocturnal SMPG measurements was assessed by considering the differences between PG values available at bedtime, at 4 AM and the before breakfast value the following day: (4 AM PG value minus at bedtime PG value), (before breakfast PG value minus at bedtime PG value) and (before breakfast PG value minus 4 AM PG value). Change from baseline in nocturnal increments in SMPG measurements of the 7-7-9 point SMPG profile was evaluated after 16 weeks of randomisation and presented during three different time intervals as follows: 1) 04:00 to breakfast, 2) bedtime to 04:00, and 3) bedtime to breakfast. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 16
Reported as:
Mean · mmol/L
Change From Baseline of the 7-7-9 Point SMPG Profile: in Nocturnal SMPG Measurements
mmol/LFaster AspartNovoRapid
04:00 to breakfast (Baseline)-1.29 ± 3.61-1.06 ± 3.35
Bedtime to 04:00 (Baseline)-0.97 ± 5.16-0.56 ± 3.84
Bedtime to breakfast (Baseline)-1.73 ± 4.81-1.56 ± 3.83
04:00 to breakfast (Change from baseline)-0.50 ± 4.83-0.08 ± 4.45
Bedtime to 04:00 (Change from baseline)0.81 ± 6.590.18 ± 5.14
Bedtime to breakfast (Change from baseline)0.13 ± 6.67-0.20 ± 5.84
SecondaryPercentage of Subjects Reaching Overall PPG (1 Hour) ≤7.8 mmol/L [140 mg/dL]

Percentage of subjects reaching overall PPG (1 hour) ≤7.8 mmol/L \[140 mg/dL\] was evaluated after 16 weeks of randomisation. Subjects without a postprandial glucose measurement at week 16 were considered not to have achieved HbA1c target at week 16. The results are based on the in-trial period.

Time frame:
Week 16
Reported as:
Number · % of subjects
Percentage of Subjects Reaching Overall PPG (1 Hour) ≤7.8 mmol/L [140 mg/dL]
% of subjectsFaster AspartNovoRapid
Percentage of Subjects Reaching Overall PPG (1 Hour) ≤7.8 mmol/L [140 mg/dL]8.17.6
SecondaryPercentage of Subjects Reaching Overall PPG (1 Hour) ≤7.8 mmol/L [140 mg/dL] Without Severe Hypoglycaemia

Percentage of subjects reaching overall PPG (1 hour) ≤7.8 mmol/L \[140 mg/dL\] without treatment emergent severe hypoglycaemia was evaluated after 16 weeks of randomisation. Subjects without a postprandial glucose measurement at week 16 were considered not to have achieved HbA1c target at week 16. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose (PG) concentrations may not be available during an event, but neurological recovery following the return of PG to normal was considered sufficient evidence that the event was induced by a low PG concentration. The results are based on the in-trial period.

Time frame:
Week 16
Reported as:
Number · % of subjects
Percentage of Subjects Reaching Overall PPG (1 Hour) ≤7.8 mmol/L [140 mg/dL] Without Severe Hypoglycaemia
% of subjectsFaster AspartNovoRapid
Percentage of Subjects Reaching Overall PPG (1 Hour) ≤7.8 mmol/L [140 mg/dL] Without Severe Hypoglycaemia7.66.8
SecondaryChange From Baseline in Lipids-lipoproteins Profile (Total Cholesterol, High Density Lipoproteins, Low Density Lipoproteins)

Reported results are lipids-lipoproteins (total cholesterol, high density lipoproteins, low density lipoproteins) values at baseline (week 0) and after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 16
Reported as:
Median · mmol/L
Change From Baseline in Lipids-lipoproteins Profile (Total Cholesterol, High Density Lipoproteins, Low Density Lipoproteins)
mmol/LFaster AspartNovoRapid
Total cholesterol (Baseline)4.48 (2.6 to 8.1)4.68 (2.9 to 8.0)
High density lipoproteins (Baseline)1.70 (0.8 to 3.3)1.71 (0.8 to 3.8)
Low density lipoproteins (Baseline)2.46 (1.1 to 6.4)2.63 (1.2 to 6.6)
Total cholesterol (Last in-trial value)4.61 (2.8 to 7.2)4.57 (2.4 to 8.2)
High density lipoproteins (Last in-trial value)1.74 (0.9 to 3.1)1.74 (0.7 to 3.6)
Low density lipoproteins (Last in-trial value)2.56 (1.0 to 5.2)2.59 (1.1 to 6.4)
SecondaryInsulin Dose in Units/Day: Total Basal

Total basal insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period: the observation period from date of first dose of randomised trial products (faster aspart and NovoRapid®) to no later than 7 days after the day of last dose of randomised trial products.

Time frame:
Week 16
Reported as:
Mean · Unit (U)
Insulin Dose in Units/Day: Total Basal
Unit (U)Faster AspartNovoRapid
Insulin Dose in Units/Day: Total Basal23.82 ± 12.8223.87 ± 11.38
SecondaryInsulin Dose in Units/Day: Total Bolus

Total bolus insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 16
Reported as:
Mean · U
Insulin Dose in Units/Day: Total Bolus
UFaster AspartNovoRapid
Insulin Dose in Units/Day: Total Bolus25.91 ± 17.4625.27 ± 15.33
SecondaryInsulin Dose in Units/Day: Total Daily Insulin Dose

Total insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 16
Reported as:
Mean · U
Insulin Dose in Units/Day: Total Daily Insulin Dose
UFaster AspartNovoRapid
Insulin Dose in Units/Day: Total Daily Insulin Dose49.72 ± 27.0849.12 ± 23.75
SecondaryInsulin Dose in Units/Day: Individual Meal Insulin Dose

No data was collected for individual meal insulin dose.

Time frame:
Week 16

No measurements were reported for this outcome.

SecondaryInsulin Dose in Units/kg/Day: Total Basal

Total basal insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 16
Reported as:
Mean · U/Kg
Insulin Dose in Units/kg/Day: Total Basal
U/KgFaster AspartNovoRapid
Insulin Dose in Units/kg/Day: Total Basal0.30 ± 0.120.30 ± 0.11
SecondaryInsulin Dose in Units/kg/Day: Total Bolus

Total bolus insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 16
Reported as:
Mean · U/Kg
Insulin Dose in Units/kg/Day: Total Bolus
U/KgFaster AspartNovoRapid
Insulin Dose in Units/kg/Day: Total Bolus0.33 ± 0.170.31 ± 0.16
SecondaryInsulin Dose in Units/kg/Day: Total Daily Insulin Dose

Total insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 16
Reported as:
Mean · U/Kg
Insulin Dose in Units/kg/Day: Total Daily Insulin Dose
U/KgFaster AspartNovoRapid
Insulin Dose in Units/kg/Day: Total Daily Insulin Dose0.63 ± 0.240.61 ± 0.23
SecondaryInsulin Dose in Units/kg/Day: Individual Meal Insulin Dose

No data was collected for individual meal insulin dose.

Time frame:
Week 16

No measurements were reported for this outcome.

SecondaryInsulin Delivery Pump Parameter: Insulin Carbohydrate Ratio

Insulin carbohydrate ratio was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 16
Reported as:
Mean · Gram (g)/U
Insulin Delivery Pump Parameter: Insulin Carbohydrate Ratio
Gram (g)/UFaster AspartNovoRapid
Insulin Delivery Pump Parameter: Insulin Carbohydrate Ratio9.13 ± 3.209.74 ± 6.77
SecondaryInsulin Delivery Pump Parameter: Glucose Sensitivity Factor

Glucose sensitivity factor was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 16
Reported as:
Mean · mmol/L/U
Insulin Delivery Pump Parameter: Glucose Sensitivity Factor
mmol/L/UFaster AspartNovoRapid
Insulin Delivery Pump Parameter: Glucose Sensitivity Factor2.65 ± 1.142.60 ± 0.98
SecondaryInsulin Delivery Pump Parameter: Active Insulin Time

Active insulin time was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 16
Reported as:
Mean · Hour (h)
Insulin Delivery Pump Parameter: Active Insulin Time
Hour (h)Faster AspartNovoRapid
Insulin Delivery Pump Parameter: Active Insulin Time3.6 ± 0.73.6 ± 0.7
SecondaryChange From Baseline in Mean IG Increment (0-30 Min, 0-1 Hour and 0-2 Hours After Start of Meal) (Mean, Breakfast, Lunch and Main Evening Meal)

Change from baseline (week 0) in mean interstitial glucose (IG) increment (0-30 minutes (min), 0-1 hour (h) and 0-2 h after start of meal) (breakfast, lunch, main evening meal and mean across all meals) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 16
Reported as:
Mean · mmol/L
Change From Baseline in Mean IG Increment (0-30 Min, 0-1 Hour and 0-2 Hours After Start of Meal) (Mean, Breakfast, Lunch and Main Evening Meal)
mmol/LFaster AspartNovoRapid
Breakfast 0-30 min (Baseline)0.23 ± 0.610.21 ± 0.60
Lunch 0-30 min (Baseline)0.02 ± 0.540.03 ± 0.60
Main evening meal 0-30 min (Baseline)0.15 ± 0.520.09 ± 0.57
Mean across all meals 0-30 min (Baseline)0.13 ± 0.370.11 ± 0.39
Breakfast 0-1 h (Baseline)0.78 ± 0.970.73 ± 0.94
Lunch 0-1 h (Baseline)0.42 ± 0.770.44 ± 0.84
Main evening meal 0-1 h (Baseline)0.39 ± 0.750.32 ± 0.82
Mean across all meals 0-1 h (Baseline)0.52 ± 0.570.50 ± 0.60
Breakfast 0-2 h (Baseline)1.32 ± 1.521.27 ± 1.46
Lunch 0-2 h (Baseline)0.99 ± 1.190.92 ± 1.07
Main evening meal 0-2 h (Baseline)0.54 ± 1.150.50 ± 1.19
Mean across all meals 0-2 h (Baseline)0.93 ± 0.940.89 ± 0.84
Breakfast 0-30 min (Change from baseline)-0.03 ± 0.800.08 ± 0.67
Lunch 0-30 min (Change from baseline)0.05 ± 0.610.10 ± 0.68
Main evening meal 0-30 min (Change from baseline)-0.07 ± 0.73-0.01 ± 0.70
Mean across all meals 0-30min:Change from baseline-0.01 ± 0.460.06 ± 0.46
Breakfast 0-1 h (Change from baseline)-0.13 ± 1.130.14 ± 0.99
Lunch 0-1 h (Change from baseline)-0.02 ± 0.880.15 ± 0.99
Main evening meal 0-1 h (Change from baseline)-0.16 ± 0.950.04 ± 0.97
Mean across all meals 0-1 h (Change from baseline)-0.10 ± 0.610.11 ± 0.66
Breakfast 0-2 h (Change from baseline)-0.28 ± 1.600.16 ± 1.45
Lunch 0-2 h (Change from baseline)-0.24 ± 1.320.22 ± 1.37
Main evening meal 0-2 h (Change from baseline)-0.29 ± 1.29-0.03 ± 1.27
Mean across all meals 0-2 h (Change from baseline)-0.25 ± 0.810.12 ± 0.86
SecondaryChange From Baseline in Mean Time to the IG Peak After Start of Meal (Mean, Breakfast, Lunch and Main Evening Meal)

Change from baseline (week 0) in mean time to the IG peak after start of meal (breakfast, lunch, main evening meal and mean across all meals) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 16
Reported as:
Mean · Minutes
Change From Baseline in Mean Time to the IG Peak After Start of Meal (Mean, Breakfast, Lunch and Main Evening Meal)
MinutesFaster AspartNovoRapid
Breakfast (Baseline)88.95 ± 25.6697.29 ± 32.32
Lunch (Baseline)109.47 ± 31.78106.94 ± 29.67
Main evening meal (Baseline)110.11 ± 32.35106.91 ± 29.61
Mean across all meals (Baseline)103.24 ± 18.50103.99 ± 19.21
Breakfast (Change from baseline)0.25 ± 33.69-4.03 ± 35.49
Lunch (Change from baseline)-2.00 ± 38.631.64 ± 38.02
Main evening meal (Change from baseline)-2.04 ± 40.51-1.43 ± 38.94
Mean across all meals (Change from baseline)-1.30 ± 22.01-1.00 ± 21.90
SecondaryChange From Baseline in Mean IG Peak After Start of Meal (Mean, Breakfast, Lunch and Main Evening Meal)

Change from baseline (week 0) in mean IG peak after start of meal (breakfast, lunch, main evening meal and mean across all meals) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 16
Reported as:
Mean · mmol/L
Change From Baseline in Mean IG Peak After Start of Meal (Mean, Breakfast, Lunch and Main Evening Meal)
mmol/LFaster AspartNovoRapid
Breakfast (Baseline)12.43 ± 1.9712.25 ± 2.09
Lunch (Baseline)12.42 ± 2.0712.56 ± 1.84
Main evening meal (Baseline)12.65 ± 2.1012.70 ± 2.06
Mean across all meals (Baseline)12.49 ± 1.6712.51 ± 1.60
Breakfast (Change from baseline)0.10 ± 2.240.11 ± 2.11
Lunch (Change from baseline)0.10 ± 2.190.19 ± 1.92
Main evening meal (Change from baseline)0.22 ± 2.09-0.13 ± 2.14
Mean across all meals (Change from baseline)0.16 ± 1.630.03 ± 1.59
SecondaryPercentage of Time Spent With IG ≤2.5, 3.0, 3.5, 3.9 mmol/L [45, 54, 63, 70 mg/dL]) and IG >10.0, 12.0, 13.9 mmol/L [180, 216, 250 mg/dL])

Percentage of time spent with IG ≤2.5, 3.0, 3.5, 3.9 mmol/L \[45, 54, 63, 70 mg/dL\]) and IG \>10.0, 12.0, 13.9 mmol/L \[180, 216, 250 mg/dL\]) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 16
Reported as:
Mean · % of time
Percentage of Time Spent With IG ≤2.5, 3.0, 3.5, 3.9 mmol/L [45, 54, 63, 70 mg/dL]) and IG >10.0, 12.0, 13.9 mmol/L [180, 216, 250 mg/dL])
% of timeFaster AspartNovoRapid
IG ≤2.5 mmol/L (45 mg/dL)1.11 ± 1.291.03 ± 1.38
IG ≤3.0 mmol/L (54 mg/dL)2.15 ± 1.982.19 ± 2.25
IG ≤3.5 mmol/L (63 mg/dL)3.75 ± 2.853.93 ± 3.37
IG ≤3.9 mmol/L (70.2 mg/dL)5.46 ± 3.685.76 ± 4.25
IG >10.0 mmol/L (180 mg/dL)41.57 ± 13.0939.24 ± 11.86
IG >12.0 mmol/L (216 mg/dL)26.34 ± 11.6624.23 ± 10.75
IG >13.9 mmol/L (250 mg/dL)15.87 ± 9.4214.23 ± 8.49
SecondaryIncidence of Episodes With IG ≤2.5, 3.0, 3.5, 3.9 mmol/L [45, 54, 63, 70 mg/dL]) and IG >10.0, 12.0, 13.9 mmol/L [180, 216, 250 mg/dL])

Incidence of episodes with IG ≤2.5, 3.0, 3.5, 3.9 mmol/L \[45, 54, 63, 70 mg/dL\]) and IG \>10.0, 12.0, 13.9 mmol/L \[180, 216, 250 mg/dL\]) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 16
Reported as:
Number · Number of Events
Incidence of Episodes With IG ≤2.5, 3.0, 3.5, 3.9 mmol/L [45, 54, 63, 70 mg/dL]) and IG >10.0, 12.0, 13.9 mmol/L [180, 216, 250 mg/dL])
Number of EventsFaster AspartNovoRapid
IG ≤2.5 mmol/L (45 mg/dL)15701532
IG ≤3.0 mmol/L (54 mg/dL)28482920
IG ≤3.5 mmol/L (63 mg/dL)45844742
IG ≤3.9 mmol/L (70 mg/dL)63716576
IG >10.0 mmol/L (180 mg/dL)3519433176
IG >12.0 mmol/L (216 mg/dL)2307021276
IG >13.9 mmol/L (250 mg/dL)1435212866
SecondaryChange From Baseline in Mean of the IG Profile

Change from baseline (week 0) in mean of the IG profile was evaluated after 16 weeks of randomisation. The mean of an IG profile is defined as the time integral of the profile over the profile's length, divided by the profile's length. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 16
Reported as:
Mean · mmol/L
Change From Baseline in Mean of the IG Profile
mmol/LFaster AspartNovoRapid
Baseline9.38 ± 1.189.39 ± 1.20
Change from baseline0.28 ± 1.270.04 ± 1.18
SecondaryPercentage of Time Spent Within IG Target Range 4.0-7.8 mmol/L (71-140 mg/dL) and 4.0-10 mmol/L (71-180 mg/dL)

Percentage of time spent within IG target range 4.0-7.8 mmol/L (71-140 mg/dL) and 4.0-10 mmol/L (71-180 mg/dL) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 16
Reported as:
Mean · % of time
Percentage of Time Spent Within IG Target Range 4.0-7.8 mmol/L (71-140 mg/dL) and 4.0-10 mmol/L (71-180 mg/dL)
% of timeFaster AspartNovoRapid
IG 4.0-7.8 mmol/L (71-140 mg/dL)31.49 ± 9.9733.11 ± 8.76
IG 4.0-10.0 mmol/L (71-180 mg/dL)52.40 ± 11.8754.40 ± 10.70
SecondaryVariation in the IG Profile

Variation in IG profile was the average absolute difference from the mean of the IG profile. Variation in the IG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 16
Reported as:
Median · mmol/L
Variation in the IG Profile
mmol/LFaster AspartNovoRapid
Variation in the IG Profile3.09 (1.6 to 5.6)3.04 (1.6 to 5.1)
SecondaryArea Under the Curve (AUC3.9-IG) for IG ≤3.9 mmol/L [70 mg/dL]

Area under the curve (AUC3.9-IG) for IG ≤3.9 mmol/L \[70 mg/dL\] was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 16
Reported as:
Mean · mmol/L
Area Under the Curve (AUC3.9-IG) for IG ≤3.9 mmol/L [70 mg/dL]
mmol/LFaster AspartNovoRapid
Area Under the Curve (AUC3.9-IG) for IG ≤3.9 mmol/L [70 mg/dL]3.19 ± 0.223.21 ± 0.20
SecondaryChange From Baseline in AUCIG,0-15min

Change from baseline (week 0) in area under the curve for interstitial glucose (AUCIG),0-15 minutes during meal test was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 16
Reported as:
Mean · mmol/L
Change From Baseline in AUCIG,0-15min
mmol/LFaster AspartNovoRapid
Baseline7.55 ± 2.637.37 ± 2.20
Change from baseline0.16 ± 3.060.21 ± 2.96
SecondaryChange From Baseline in AUCIG,0-30min

Change from baseline (week 0) in AUCIG,0-30 minutes during meal test was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 16
Reported as:
Mean · mmol/L
Change From Baseline in AUCIG,0-30min
mmol/LFaster AspartNovoRapid
Baseline7.98 ± 2.657.86 ± 2.25
Change from baseline0.12 ± 3.120.22 ± 3.02
SecondaryChange From Baseline in AUCIG,0-1h

Change from baseline (week 0) in AUCIG,0-1 hour during meal test was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 16
Reported as:
Mean · mmol/L
Change From Baseline in AUCIG,0-1h
mmol/LFaster AspartNovoRapid
Baseline9.47 ± 2.769.35 ± 2.38
Change from baseline-0.07 ± 3.330.32 ± 3.26
SecondaryChange From Baseline in AUCIG,0-2h

Change from baseline (week 0) in AUCIG,0-2 hours during meal test was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 16
Reported as:
Mean · mmol/L
Change From Baseline in AUCIG,0-2h
mmol/LFaster AspartNovoRapid
Baseline11.27 ± 3.1011.18 ± 2.82
Change from baseline-0.38 ± 3.760.37 ± 3.90
SecondaryChange From Baseline in AUCIG,0-4h

Change from baseline (week 0) in AUCIG,0-24hours during meal test was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 16
Reported as:
Mean · mmol/L
Change From Baseline in AUCIG,0-4h
mmol/LFaster AspartNovoRapid
Baseline11.31 ± 3.3311.40 ± 3.03
Change from baseline-0.32 ± 4.070.29 ± 4.10
SecondaryChange From Baseline in Time to the IG Peak After Start of Meal

Change from baseline (week 0) in time to the IG peak after start of meal-test meal was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 16
Reported as:
Mean · Minute
Change From Baseline in Time to the IG Peak After Start of Meal
MinuteFaster AspartNovoRapid
Baseline111.2 ± 45.3117.0 ± 43.0
Change from baseline1.2 ± 50.5-1.4 ± 51.6
SecondaryChange From Baseline in IG Peak After Start of Meal

Change from baseline (week 0) in IG peak after start of meal-test meal was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 16
Reported as:
Mean · mmol/L
Change From Baseline in IG Peak After Start of Meal
mmol/LFaster AspartNovoRapid
Baseline14.71 ± 3.9414.69 ± 3.65
Change from baseline-0.57 ± 4.690.36 ± 4.78
SecondaryNumber of Treatment Emergent Adverse Events (AEs)

Treatment emergent adverse events (TEAEs) were recorded from week 0 to week 16. A TEAE was defined as an event that has an onset date on or after the first day of exposure to randomised treatment (in week 0), and no later than seven days after the last day of randomised treatment (i.e., maximum week 16 + 7 days). The results are based on the on-treatment period.

Time frame:
Weeks 0-16
Reported as:
Number · Number of adverse events
Number of Treatment Emergent Adverse Events (AEs)
Number of adverse eventsFaster AspartNovoRapid
Number of Treatment Emergent Adverse Events (AEs)440412
SecondaryNumber of Treatment Emergent Infusion Site Reactions

Number of treatment emergent infusion site reactions were recorded from week 0 to week 16. The results are based on the on-treatment period.

Time frame:
Weeks 0-16
Reported as:
Number · Number of infusion site reaction events
Number of Treatment Emergent Infusion Site Reactions
Number of infusion site reaction eventsFaster AspartNovoRapid
Number of Treatment Emergent Infusion Site Reactions4432
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association (ADA) and Novo Nordisk (NN) Definition: Overall

ADA classification of hypo: 1. Severe: Requiring assistance of another person to actively administer carbohydrate/glucagon/take other corrective actions. PG levels may not be available during an event, but neurological recovery following return of PG to normal is considered sufficient evidence that event was induced by a low PG level. 2. Documented symptomatic: PG ≤3.9 mmol/L with symptoms. 3. Asymptomatic: PG ≤3.9 mmol/L without symptoms. 4. Probable symptomatic: No measurement with symptoms. 5. Pseudo: PG \>3.9 mmol/L with symptoms. 6. Unclassifiable. NN classification of hypo: 1. BG confirmed: PG \<3.1 mmol/L with/without symptoms. 2. Severe or BG confirmed symptomatic: Severe as per ADA and BG confirmed by PG \<3.1 mmol/L with symptoms. 3. Severe or BG confirmed: Severe as per ADA and BG confirmed by PG \<3.1 mmol/L with/without symptoms. 4. Unclassifiable. Not able to self treat-unclassifiable: Not able to self treat but not classifiable as severe hypo.

Time frame:
Weeks 0-16
Reported as:
Number · Number of hypoglycaemic episodes
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association (ADA) and Novo Nordisk (NN) Definition: Overall
Number of hypoglycaemic episodesFaster AspartNovoRapid
ADA: Severe217
ADA: Documented symptomatic83728904
ADA: Asymptomatic25302273
ADA: Probable symptomatic8832
ADA: Pseudo56159
ADA: Unclassifiable10
NN: BG confirmed32583240
NN: Severe or BG confirmed symptomatic27512779
NN: Severe or BG confirmed32793247
NN: Unclassifiable77898128
Not able to selftreat - unclassifiable00
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Daytime Hypoglycaemic Episodes (06:00-00:00 - Inclusive)

Number of treatment emergent day time hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 06:00 and 00:00 (both included). The results are based on the on-treatment period.

Time frame:
Weeks 0-16
Reported as:
Number · Number of hypoglycaemic episodes
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Daytime Hypoglycaemic Episodes (06:00-00:00 - Inclusive)
Number of hypoglycaemic episodesFaster AspartNovoRapid
ADA: Severe125
ADA: Documented symptomatic75087889
ADA: Asymptomatic23212071
ADA: Probable symptomatic7026
ADA: Pseudo52144
ADA: Unclassifiable00
NN: BG confirmed27992769
NN: Severe or BG confirmed symptomatic23352359
NN: Severe or BG confirmed28112774
NN: Unclassifiable71527361
Not able to selftreat - unclassifiable00
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Nocturnal Hypoglycaemic Episodes (00:01-05:59 - Inclusive)

Number of treatment emergent nocturnal hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 00:01 and 05:59 (both included). The results are based on the on-treatment period.

Time frame:
Weeks 0-16
Reported as:
Number · Number of hypoglycaemic episodes
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Nocturnal Hypoglycaemic Episodes (00:01-05:59 - Inclusive)
Number of hypoglycaemic episodesFaster AspartNovoRapid
ADA: Severe92
ADA: Documented symptomatic8641015
ADA: Asymptomatic209202
ADA: Probable symptomatic186
ADA: Pseudo415
ADA: Unclassifiable10
NN: BG confirmed459471
NN: Severe or BG confirmed symptomatic416420
NN: Severe or BG confirmed468473
NN: Unclassifiable637767
Not able to selftreat - unclassifiable00
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 1 Hour After Start of the Meal

Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 1 hour after start of the meal. The results are based on the on-treatment period.

Time frame:
Weeks 0-16
Reported as:
Number · Number of hypoglycaemic episodes
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 1 Hour After Start of the Meal
Number of hypoglycaemic episodesFaster AspartNovoRapid
ADA: Severe00
ADA: Documented symptomatic224190
ADA: Asymptomatic3133
ADA: Probable symptomatic13
ADA: Pseudo05
ADA: Unclassifiable00
NN: BG confirmed9251
NN: Severe or BG confirmed symptomatic8148
NN: Severe or BG confirmed9251
NN: Unclassifiable164180
Not able to selftreat - unclassifiable00
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes During First 2 Hours After Start of the Meal

Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 2 hours after start of the meal. The results are based on the on-treatment period.

Time frame:
Weeks 0-16
Reported as:
Number · Number of hypoglycaemic episodes
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes During First 2 Hours After Start of the Meal
Number of hypoglycaemic episodesFaster AspartNovoRapid
ADA: Severe00
ADA: Documented symptomatic12581077
ADA: Asymptomatic176175
ADA: Probable symptomatic96
ADA: Pseudo734
ADA: Unclassifiable00
NN: BG confirmed482413
NN: Severe or BG confirmed symptomatic441372
NN: Severe or BG confirmed482413
NN: Unclassifiable968879
Not able to selftreat - unclassifiable00
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes During First 4 Hours After Start of the Meal

Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 4 hours after start of the meal. The results are based on the on-treatment period.

Time frame:
Weeks 0-16
Reported as:
Number · Number of hypoglycaemic episodes
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes During First 4 Hours After Start of the Meal
Number of hypoglycaemic episodesFaster AspartNovoRapid
ADA: Severe52
ADA: Documented symptomatic37673907
ADA: Asymptomatic750677
ADA: Probable symptomatic4317
ADA: Pseudo2998
ADA: Unclassifiable00
NN: BG confirmed14031399
NN: Severe or BG confirmed symptomatic12461259
NN: Severe or BG confirmed14081401
NN: Unclassifiable31863300
Not able to selftreat - unclassifiable00
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes Occurring Between 2 to 4 Hours After Start of the Meal

Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 2 to 4 hours after start of the meal. The results are based on the on-treatment period.

Time frame:
Weeks 0-16
Reported as:
Number · Number of hypoglycaemic episodes
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes Occurring Between 2 to 4 Hours After Start of the Meal
Number of hypoglycaemic episodesFaster AspartNovoRapid
ADA: Severe52
ADA: Documented symptomatic25092830
ADA: Asymptomatic574502
ADA: Probable symptomatic3411
ADA: Pseudo2264
ADA: Unclassifiable00
NN: BG confirmed921986
NN: Severe or BG confirmed symptomatic805887
NN: Severe or BG confirmed926988
NN: Unclassifiable22182421
Not able to selftreat - unclassifiable00
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes Occurring Between 1 Hour to 2 Hours After Start of the Meal

Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 1 hour to 2 hours after start of the meal. The results are based on the on-treatment period.

Time frame:
Weeks 0-16
Reported as:
Number · Number of hypoglycaemic episodes
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes Occurring Between 1 Hour to 2 Hours After Start of the Meal
Number of hypoglycaemic episodesFaster AspartNovoRapid
ADA: Severe00
ADA: Documented symptomatic1034887
ADA: Asymptomatic145142
ADA: Probable symptomatic83
ADA: Pseudo729
ADA: Unclassifiable00
NN: BG confirmed390362
NN: Severe or BG confirmed symptomatic360324
NN: Severe or BG confirmed390362
NN: Unclassifiable804699
Not able to selftreat - unclassifiable00
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes Occurring Between 2 to 3 Hours After Start of the Meal

Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 2 to 3 hours after start of the meal. The results are based on the on-treatment period.

Time frame:
Weeks 0-16
Reported as:
Number · Number of hypoglycaemic episodes
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes Occurring Between 2 to 3 Hours After Start of the Meal
Number of hypoglycaemic episodesFaster AspartNovoRapid
ADA: Severe21
ADA: Documented symptomatic13271518
ADA: Asymptomatic277241
ADA: Probable symptomatic197
ADA: Pseudo1338
ADA: Unclassifiable00
NN: BG confirmed491555
NN: Severe or BG confirmed symptomatic429508
NN: Severe or BG confirmed493556
NN: Unclassifiable11451249
Not able to selftreat - unclassifiable00
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes Occurring Between 3 to 4 Hours After Start of the Meal

Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 3 to 4 hours after start of the meal. The results are based on the on-treatment period.

Time frame:
Weeks 0-16
Reported as:
Number · Number of hypoglycaemic episodes
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes Occurring Between 3 to 4 Hours After Start of the Meal
Number of hypoglycaemic episodesFaster AspartNovoRapid
ADA: Severe31
ADA: Documented symptomatic11821312
ADA: Asymptomatic297261
ADA: Probable symptomatic154
ADA: Pseudo926
ADA: Unclassifiable00
NN: BG confirmed430431
NN: Severe or BG confirmed symptomatic376379
NN: Severe or BG confirmed433432
NN: Unclassifiable10731172
Not able to selftreat - unclassifiable00
SecondaryNumber of Unexplained Episodes of Hyperglycaemia (Confirmed by SMPG)

Unexplained hyperglycaemia was defined as a confirmed PG value ≥16.7 mmol/L (300 mg/dL) and was unexplained (i.e. no apparent medical, dietary, insulin dosage or pump failure reason). The results are based on the on-treatment period.

Time frame:
Weeks 0-16
Reported as:
Number · Number of hypoglycaemic episodes
Number of Unexplained Episodes of Hyperglycaemia (Confirmed by SMPG)
Number of hypoglycaemic episodesFaster AspartNovoRapid
Number of Unexplained Episodes of Hyperglycaemia (Confirmed by SMPG)11851058
SecondaryChange From Baseline in Physical Examination: Respiratory System

Reported results are respiratory system-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Number · Number of subjects
Change From Baseline in Physical Examination: Respiratory System
Number of subjectsFaster AspartNovoRapid
Normal, baseline234235
Abnormal (NCS), baseline11
Abnormal (CS), baseline10
Normal, last on-treatment value235234
Abnormal (NCS), last on-treatment value02
Abnormal (CS), last on-treatment value10
SecondaryChange From Baseline in Physical Examination: Cardiovascular System

Reported results are cardiovascular system-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Number · Number of subjects
Change From Baseline in Physical Examination: Cardiovascular System
Number of subjectsFaster AspartNovoRapid
Normal, baseline233229
Abnormal (NCS), baseline17
Abnormal (CS), baseline20
Normal, last on-treatment value231228
Abnormal (NCS), last on-treatment value47
Abnormal (CS), last on-treatment value11
SecondaryChange From Baseline in Physical Examination: Central and Peripheral Nervous System

Reported results are central and peripheral nervous system-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Number · Number of subjects
Change From Baseline in Physical Examination: Central and Peripheral Nervous System
Number of subjectsFaster AspartNovoRapid
Normal, baseline210215
Abnormal (NCS), baseline2218
Abnormal (CS), baseline43
Normal, last on-treatment value209216
Abnormal (NCS), last on-treatment value2317
Abnormal (CS), last on-treatment value43
SecondaryChange From Baseline in Physical Examination: Gastrointestinal System, Including the Mouth

Reported results are gastrointestinal system-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Number · Number of subjects
Change From Baseline in Physical Examination: Gastrointestinal System, Including the Mouth
Number of subjectsFaster AspartNovoRapid
Normal, baseline231231
Abnormal (NCS), baseline35
Abnormal (CS), baseline20
Normal, last on-treatment value231231
Abnormal (NCS), last on-treatment value43
Abnormal (CS), last on-treatment value12
SecondaryChange From Baseline in Physical Examination: Musculoskeletal System

Reported results are musculoskeletal system-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Number · Number of subjects
Change From Baseline in Physical Examination: Musculoskeletal System
Number of subjectsFaster AspartNovoRapid
Normal, baseline222227
Abnormal (NCS), baseline139
Abnormal (CS), baseline10
Normal, last on-treatment value223228
Abnormal (NCS), last on-treatment value128
Abnormal (CS), last on-treatment value10
SecondaryChange From Baseline in Physical Examination: Skin

Reported results are skin-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Number · Number of subjects
Change From Baseline in Physical Examination: Skin
Number of subjectsFaster AspartNovoRapid
Normal, baseline212211
Abnormal (NCS), baseline1822
Abnormal (CS), baseline63
Normal, last on-treatment value204203
Abnormal (NCS), last on-treatment value2129
Abnormal (CS), last on-treatment value114
SecondaryChange From Baseline in Physical Examination: Head, Ears, Eyes, Nose, Throat and Neck

Reported results are head, ears, eyes, nose, throat and neck-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Number · Number of subjects
Change From Baseline in Physical Examination: Head, Ears, Eyes, Nose, Throat and Neck
Number of subjectsFaster AspartNovoRapid
Normal, baseline219221
Abnormal (NCS), baseline1514
Abnormal (CS), baseline21
Normal, last on-treatment value217218
Abnormal (NCS), last on-treatment value1516
Abnormal (CS), last on-treatment value42
SecondaryChange From Baseline in Vital Sign: Blood Pressure

Change from baseline (week 0) in blood pressure (both systolic and diastolic) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Mean · mmHg
Change From Baseline in Vital Sign: Blood Pressure
mmHgFaster AspartNovoRapid
Systolic blood pressure (baseline)123.6 ± 14.7122.0 ± 14.3
Diastolic blood pressure (baseline)74.8 ± 9.474.6 ± 8.7
Systolic blood pressure (change from baseline)-0.8 ± 12.3-0.7 ± 11.5
Diastolic blood pressure (change from baseline)-0.7 ± 8.4-0.4 ± 7.7
SecondaryChange From Baseline in Vital Sign: Pulse

Change from baseline (week 0) in pulse was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Mean · Beats/minute
Change From Baseline in Vital Sign: Pulse
Beats/minuteFaster AspartNovoRapid
Baseline73.7 ± 11.074.5 ± 11.1
Change from baseline-0.5 ± 9.0-0.8 ± 9.6
SecondaryChange From Screening in Electrocardiogram (ECG)

Reported results are ECG findings at screening (week -6) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Number · Number of subjects
Change From Screening in Electrocardiogram (ECG)
Number of subjectsFaster AspartNovoRapid
Normal, screening178181
Abnormal (NCS), screening5854
Abnormal (CS), screening01
Normal, last on-treatment value188180
Abnormal (NCS), last on-treatment value4448
Abnormal (CS), last on-treatment value02
SecondaryChange From Screening in Fundus Photography/Fundoscopy

Reported results are fundus photography/fundoscopy (for both left and right eye) findings at screening (week -6) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) AAbnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Number · Number of subjects
Change From Screening in Fundus Photography/Fundoscopy
Number of subjectsFaster AspartNovoRapid
Left eye (Normal), screening135136
Left eye (Abnormal [NCS]), screening9494
Left eye (Abnormal [CS]), screening76
Right eye (Normal), screening132132
Right eye (Abnormal [NCS]), screening9898
Right eye (Abnormal [CS]), screening66
Left eye (Normal), last on-treatment value130119
Left eye (Abnormal [NCS]), last on-treatment value7782
Left eye (Abnormal [CS] last on-treatment value107
Right eye (Normal), last on-treatment value127114
Right eye (Abnormal-NCS), last on-treatment value8087
Right eye (Abnormal [CS]), last on-treatment value107
SecondaryChange From Baseline in Haematology: Haemoglobin

Change from baseline (week 0) in haemoglobin was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Mean · mmol/L
Change From Baseline in Haematology: Haemoglobin
mmol/LFaster AspartNovoRapid
Baseline8.62 ± 0.828.62 ± 0.80
Change from baseline-0.01 ± 0.48-0.06 ± 0.40
SecondaryChange From Baseline in Haematology: Haematocrit

Change from baseline (week 0) in haematocrit was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Mean · % of haematocrit
Change From Baseline in Haematology: Haematocrit
% of haematocritFaster AspartNovoRapid
Baseline42.23 ± 3.9842.37 ± 3.77
Change from baseline0.09 ± 2.47-0.30 ± 2.01
SecondaryChange From Baseline in Haematology: Erythrocytes

Change from baseline (week 0) in erythrocytes was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Mean · 10^12/L
Change From Baseline in Haematology: Erythrocytes
10^12/LFaster AspartNovoRapid
Baseline4.66 ± 0.454.72 ± 0.42
Change from baseline0.01 ± 0.27-0.03 ± 0.22
SecondaryChange From Baseline in Haematology: Thrombocytes

Change from baseline (week 0) in thrombocytes was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Mean · 10^9/L
Change From Baseline in Haematology: Thrombocytes
10^9/LFaster AspartNovoRapid
Baseline246.4 ± 58.9243.6 ± 55.3
Change from baseline2.2 ± 33.50.2 ± 35.8
SecondaryChange From Baseline in Haematology: Leucocytes

Change from baseline (week 0) in leucocytes was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Mean · 10^9/L
Change From Baseline in Haematology: Leucocytes
10^9/LFaster AspartNovoRapid
Baseline6.41 ± 1.786.32 ± 1.70
Change from baseline-0.09 ± 1.49-0.03 ± 1.22
SecondaryChange From Baseline in Biochemistry: Total Protein

Change from baseline (week 0) in total protein was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Mean · g/dL
Change From Baseline in Biochemistry: Total Protein
g/dLFaster AspartNovoRapid
Baseline6.73 ± 0.446.74 ± 0.47
Change from baseline0.03 ± 0.36-0.05 ± 0.40
SecondaryChange From Baseline in Biochemistry: Creatinine

Change from baseline (week 0) in creatinine was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Mean · umol/L
Change From Baseline in Biochemistry: Creatinine
umol/LFaster AspartNovoRapid
Baseline73.8 ± 12.374.5 ± 13.3
Change from baseline0.9 ± 7.9-0.1 ± 8.2
SecondaryChange From Baseline in Biochemistry: Alanine Aminotransferase (ALT)

Change from baseline (week 0) in ALT was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Mean · U/L
Change From Baseline in Biochemistry: Alanine Aminotransferase (ALT)
U/LFaster AspartNovoRapid
Baseline20.0 ± 11.619.1 ± 11.5
Change from baseline0.1 ± 13.80 ± 9.4
SecondaryChange From Baseline in Biochemistry: Aspartate Aminotransferase (AST)

Change from baseline (week 0) in AST was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Mean · U/L
Change From Baseline in Biochemistry: Aspartate Aminotransferase (AST)
U/LFaster AspartNovoRapid
Baseline22.2 ± 9.120.6 ± 7.8
Change from baseline-0.1 ± 18.6-0.4 ± 8.7
SecondaryChange From Baseline in Biochemistry: Alkaline Phosphatase (ALP)

Change from baseline (week 0) in ALP was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Mean · U/L
Change From Baseline in Biochemistry: Alkaline Phosphatase (ALP)
U/LFaster AspartNovoRapid
Baseline68.8 ± 20.869.7 ± 23.9
Change from baseline1.2 ± 9.60.8 ± 10.0
SecondaryChange From Baseline in Biochemistry: Sodium

Change from baseline (week 0) in sodium was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Mean · mmol/L
Change From Baseline in Biochemistry: Sodium
mmol/LFaster AspartNovoRapid
Baseline140.3 ± 2.7140.3 ± 2.7
Change from baseline-0.2 ± 2.9-0.2 ± 2.5
SecondaryChange From Baseline in Biochemistry: Potassium

Change from baseline (week 0) in potassium was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Mean · mmol/L
Change From Baseline in Biochemistry: Potassium
mmol/LFaster AspartNovoRapid
Baseline4.34 ± 0.424.30 ± 0.39
Change from baseline-0.02 ± 0.42-0.01 ± 0.41
SecondaryChange From Baseline in Biochemistry: Albumin

Change from baseline (week 0) in albumin was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Mean · g/dL
Change From Baseline in Biochemistry: Albumin
g/dLFaster AspartNovoRapid
Baseline4.32 ± 0.274.31 ± 0.28
Change from baseline-0.01 ± 0.22-0.05 ± 0.26
SecondaryChange From Baseline in Biochemistry: Total Bilirubin

Change from baseline (week 0) in bilirubin was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Mean · umol/L
Change From Baseline in Biochemistry: Total Bilirubin
umol/LFaster AspartNovoRapid
Baseline8.2 ± 5.18.8 ± 6.4
Change from baseline-0.3 ± 3.8-1.0 ± 3.7
SecondaryChange From Baseline in Urinalysis: Albumin/Creatine Ratio

Change from baseline (week 0) in albumin/creatine ratio was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Mean · mg/mmol
Change From Baseline in Urinalysis: Albumin/Creatine Ratio
mg/mmolFaster AspartNovoRapid
Baseline2.67 ± 13.882.00 ± 7.60
Change from baseline0.01 ± 4.76-0.04 ± 3.11
SecondaryChange From Baseline in Urinalysis: Erythrocytes

Reported results are urine erythrocytes-test findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: a) Negative, b) Trace, c) 1+, d) 2+ and e) 3+. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Number · Number of subjects
Change From Baseline in Urinalysis: Erythrocytes
Number of subjectsFaster AspartNovoRapid
Negative (baseline)217215
Trace (baseline)810
1+ (baseline)55
2+ (baseline)51
3+ (baseline)15
Negative (last on-treatment value)217215
Trace (last on-treatment value)610
1+ (last on-treatment value)33
2+ (last on-treatment value)24
3+ (last on-treatment value)84
SecondaryChange From Baseline in Urinalysis: Protein

Reported results are urine protein-test findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: a) Negative, b) Trace, c) 1+, d) 2+ e) 3+ and f) 4+. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Number · Number of subjects
Change From Baseline in Urinalysis: Protein
Number of subjectsFaster AspartNovoRapid
Negative (baseline)193195
Trace (baseline)3127
1+ (baseline)810
2+ (baseline)44
3+ (baseline)00
4+ (baseline)00
Negative (last on-treatment value)196196
Trace (last on-treatment value)2727
1+ (last on-treatment value)109
2+ (last on-treatment value)24
3+ (last on-treatment value)10
4+ (last on-treatment value)00
SecondaryChange From Baseline in Urinalysis: Ketones

Reported results are urine ketone-test findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: a) Negative, b) Trace, c) 1+, d) 2+ e) 3+ and f) 4+. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Number · Number of subjects
Change From Baseline in Urinalysis: Ketones
Number of subjectsFaster AspartNovoRapid
Negative (baseline)192205
Trace (baseline)3123
1+ (baseline)118
2+ (baseline)20
3+ (baseline)00
4+ (baseline)00
Negative (last on-treatment value)194203
Trace (last on-treatment value)2527
1+ (last on-treatment value)155
2+ (last on-treatment value)21
3+ (last on-treatment value)00
4+ (last on-treatment value)00
SecondaryChange From Baseline in Body Weight

Change from baseline (week 0) in body weight was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Mean · Kg
Change From Baseline in Body Weight
KgFaster AspartNovoRapid
Baseline76.86 ± 15.2078.21 ± 14.47
Change from baseline0.34 ± 1.900.80 ± 2.14
SecondaryChange From Baseline in Body Mass Index (BMI)

Change from baseline (week 0) in BMI was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 16
Reported as:
Mean · kg/m^2
Change From Baseline in Body Mass Index (BMI)
kg/m^2Faster AspartNovoRapid
Baseline26.16 ± 4.0626.51 ± 3.89
Change from baseline0.12 ± 0.650.28 ± 0.74
SecondaryNumber of Change-of-infusion-sets Per Week

Number of change-of-infusion-sets per week was evaluated from week 0 to week 16. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0-16
Reported as:
Mean · Number of infusion-sets
Number of Change-of-infusion-sets Per Week
Number of infusion-setsFaster AspartNovoRapid
Number of Change-of-infusion-sets Per Week2.55 ± 0.432.49 ± 0.47
SecondaryNumber of Subjects With at Least One Non-routine Change-of-infusion-sets Categorised by Reasons for Change-of-infusion-sets

Number of subjects with at least one non-routine change-of-infusion-sets categorised by reasons for change-of-infusion-sets was evaluated from week 0 to week 16. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. Reasons for change-of-infusion-sets are categorised as follows: Category-1: A perceived occlusion by the subject Category-2: Any problems related to the infusion set Category-3: Any technical issues with the pump Category-4: Changes in the insulin solution in the infusion set or reservoir Category-5: High BG with no other explanation which made the subject change the infusion set Category-6: Infusion site reaction Category-7: Missing

Time frame:
Week 0-16
Reported as:
Number · Number of subjects
Number of Subjects With at Least One Non-routine Change-of-infusion-sets Categorised by Reasons for Change-of-infusion-sets
Number of subjectsFaster AspartNovoRapid
Category-15050
Category-210875
Category-32317
Category-438
Category-56660
Category-6168
Category-731

Adverse events

Collected over Week 0 to Week 16 + 7 days. All reported AEs are treatment emergent (i.e., TEAE).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Faster Aspart0/236 (0%)5/236 (2.1%)84/236 (35.6%)
NovoRapid0/236 (0%)8/236 (3.4%)72/236 (30.5%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventFaster AspartNovoRapid
Accidental overdoseInjury, poisoning and procedural complications0/2361/236
Adenovirus infectionInfections and infestations0/2361/236
AppendicitisInfections and infestations1/2360/236
Device breakageProduct Issues0/2361/236
Drug eruptionSkin and subcutaneous tissue disorders1/2360/236
HypoglycaemiaMetabolism and nutrition disorders0/2361/236
Hypoglycaemic seizureNervous system disorders0/2361/236
Hypoglycaemic unconsciousnessNervous system disorders1/2361/236
KetoacidosisMetabolism and nutrition disorders1/2360/236
NeurodermatitisSkin and subcutaneous tissue disorders0/2361/236
Most frequent other events
Most frequent other events
EventFaster AspartNovoRapid
Viral upper respiratory tract infectionInfections and infestations48/23650/236
Upper respiratory tract infectionInfections and infestations17/23612/236
Infusion site reactionGeneral disorders16/2367/236
GastroenteritisInfections and infestations12/2366/236

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Faster AspartNovoRapidTotal
Mean43.3 ± 14.843.6 ± 14.743.5 ± 14.7
Sex: Female, Male
Sex: Female, Male(Participants)Faster AspartNovoRapidTotal
Female133136269
Male103100203
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Faster AspartNovoRapidTotal
Hispanic or Latino7613
Not Hispanic or Latino210215425
Unknown or Not Reported191534
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Faster AspartNovoRapidTotal
American Indian or Alaska Native022
Asian336
Native Hawaiian or Other Pacific Islander000
Black or African American257
White209210419
More than one race000
Unknown or Not Reported221638
09

Study locations

92 sites
  • Novo Nordisk Investigational Site
    Encino, California 91436, United States
  • Novo Nordisk Investigational Site
    Fresno, California 93720, United States
  • Novo Nordisk Investigational Site
    Roseville, California 95661, United States
  • Novo Nordisk Investigational Site
    San Mateo, California 94401, United States
  • Novo Nordisk Investigational Site
    San Ramon, California 94583, United States
  • Novo Nordisk Investigational Site
    Santa Barbara, California 93105, United States
  • Novo Nordisk Investigational Site
    Walnut Creek, California 94598, United States
  • Novo Nordisk Investigational Site
    Newark, Delaware 19713, United States
  • Novo Nordisk Investigational Site
    Atlanta, Georgia 30339, United States
  • Novo Nordisk Investigational Site
    Idaho Falls, Idaho 83404-7596, United States
  • Novo Nordisk Investigational Site
    Arlington Heights, Illinois 60005-4144, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40503, United States
  • Novo Nordisk Investigational Site
    Rockville, Maryland 20852, United States
  • Novo Nordisk Investigational Site
    Boston, Massachusetts 02215, United States
  • Novo Nordisk Investigational Site
    Minneapolis, Minnesota 55416, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89148, United States
  • Novo Nordisk Investigational Site
    Nashua, New Hampshire 03063, United States
  • Novo Nordisk Investigational Site
    Albany, New York 12206, United States
  • Novo Nordisk Investigational Site
    Asheville, North Carolina 28803, United States
  • Novo Nordisk Investigational Site
    Chapel Hill, North Carolina 27517, United States
  • Novo Nordisk Investigational Site
    Pittsburgh, Pennsylvania 15224-2215, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37404-1192, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37411, United States
  • Novo Nordisk Investigational Site
    Amarillo, Texas 79106, United States
  • Novo Nordisk Investigational Site
    Austin, Texas 78749, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75231, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75246, United States
  • Novo Nordisk Investigational Site
    Mesquite, Texas 75149, United States
  • Novo Nordisk Investigational Site
    Federal Way, Washington 98003, United States
  • Novo Nordisk Investigational Site
    Renton, Washington 98057, United States
  • Novo Nordisk Investigational Site
    Arlon, 6700, Belgium
  • Novo Nordisk Investigational Site
    Bonheiden, 2820, Belgium
  • Novo Nordisk Investigational Site
    Brussels, 1090, Belgium
  • Novo Nordisk Investigational Site
    Edegem, 2650, Belgium
  • Novo Nordisk Investigational Site
    Leuven, 3000, Belgium
  • Novo Nordisk Investigational Site
    Sint-Niklaas, 9100, Belgium
  • Novo Nordisk Investigational Site
    Wilrijk, 2610, Belgium
  • Novo Nordisk Investigational Site
    Edmonton, Alberta T6G 2E1, Canada
  • Novo Nordisk Investigational Site
    Barrie, Ontario L4N 7L3, Canada
  • Novo Nordisk Investigational Site
    Concord, Ontario L4K 4M2, Canada
  • Novo Nordisk Investigational Site
    London, Ontario N6A 4V2, Canada
  • Novo Nordisk Investigational Site
    Oakville, Ontario L6M 1M1, Canada
  • Novo Nordisk Investigational Site
    Toronto, Ontario M4G 3E8, Canada
  • Novo Nordisk Investigational Site
    Montreal, Quebec H2X 0A9, Canada
  • Novo Nordisk Investigational Site
    Quebec, G1V 4G2, Canada
  • Novo Nordisk Investigational Site
    Caen, 14033, France
  • Novo Nordisk Investigational Site
    LA ROCHELLE cedex, 17019, France
  • Novo Nordisk Investigational Site
    Le Creusot, 71200, France
  • Novo Nordisk Investigational Site
    MONTPELLIER cedex 5, 34295, France
  • Novo Nordisk Investigational Site
    Narbonne, 11108, France
  • Novo Nordisk Investigational Site
    Paris, 75010, France
  • Novo Nordisk Investigational Site
    Saint Herblain, 44800, France
  • Novo Nordisk Investigational Site
    Strasbourg, 67098, France
  • Novo Nordisk Investigational Site
    TOULOUSE cedex, 31054, France
  • Novo Nordisk Investigational Site
    Venissieux, 69200, France
  • Novo Nordisk Investigational Site
    Bad Mergentheim, 97980, Germany
  • Novo Nordisk Investigational Site
    Essen, 45136, Germany
  • Novo Nordisk Investigational Site
    Friedrichsthal, 66299, Germany
  • Novo Nordisk Investigational Site
    Hamburg, 22607, Germany
  • Novo Nordisk Investigational Site
    Ludwigshafen, 67059, Germany
  • Novo Nordisk Investigational Site
    Münster, 48145, Germany
  • Novo Nordisk Investigational Site
    Neuwied, 56564, Germany
  • Novo Nordisk Investigational Site
    Rehlingen-Siersburg, 66780, Germany
  • Novo Nordisk Investigational Site
    Rostock, 18057, Germany
  • Novo Nordisk Investigational Site
    Amsterdam, 1105 AZ, Netherlands
  • Novo Nordisk Investigational Site
    Apeldoorn, 7334 DZ, Netherlands
  • Novo Nordisk Investigational Site
    Eindhoven, 5631 BM, Netherlands
  • Novo Nordisk Investigational Site
    Hoofddorp, 2134 TM, Netherlands
  • Novo Nordisk Investigational Site
    Hoogeveen, 7909 AA, Netherlands
  • Novo Nordisk Investigational Site
    Leiden, 2333 ZA, Netherlands
  • Novo Nordisk Investigational Site
    Nijmegen, 6525 GA, Netherlands
  • Novo Nordisk Investigational Site
    Rotterdam, 3011 TA, Netherlands
  • Novo Nordisk Investigational Site
    Utrecht, 3584 CX, Netherlands
  • Novo Nordisk Investigational Site
    Venlo, 5912 BL, Netherlands
  • Novo Nordisk Investigational Site
    Cheboksary, 428009, Russian Federation
  • Novo Nordisk Investigational Site
    Moscow, 117036, Russian Federation
  • Novo Nordisk Investigational Site
    Novosibirsk, 630117, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 190068, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 195257, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 199034, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 199226, Russian Federation
  • Novo Nordisk Investigational Site
    Saratov, 410039, Russian Federation
  • Novo Nordisk Investigational Site
    St. Petersburg, 194354, Russian Federation
  • Novo Nordisk Investigational Site
    Yoshkar-Ola, 424004, Russian Federation
  • Novo Nordisk Investigational Site
    Ljubljana, 1525, Slovenia
  • Novo Nordisk Investigational Site
    Novo mesto, 8000, Slovenia
  • Novo Nordisk Investigational Site
    Cambridge, CB2 0QQ, United Kingdom
  • Novo Nordisk Investigational Site
    Guildford, GU2 7XX, United Kingdom
  • Novo Nordisk Investigational Site
    Harrogate, North Yorkshire, HG2 7SX, United Kingdom
  • Novo Nordisk Investigational Site
    London, SE1 9RT, United Kingdom
  • Novo Nordisk Investigational Site
    Manchester, M13 0JE, United Kingdom
  • Novo Nordisk Investigational Site
    St Helens, WA9 3DA, United Kingdom
10

References and documents

Publications

  • Zijlstra E, Demissie M, Graungaard T, Heise T, Nosek L, Bode B. Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes. J Diabetes Sci Technol. 2018 Jan;12(1):145-151. doi: 10.1177/1932296817730375. Epub 2017 Sep 18. PubMed 28918652 ↗
  • Klonoff DC, Evans ML, Lane W, Kempe HP, Renard E, DeVries JH, Graungaard T, Hyseni A, Gondolf T, Battelino T. A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5). Diabetes Obes Metab. 2019 Apr;21(4):961-967. doi: 10.1111/dom.13610. Epub 2019 Jan 13. PubMed 30537180 ↗
  • Gorst-Rasmussen A, Sturis J, Ekelund M. Continuous Glucose Monitoring Sensor Glucose Levels and Insulin Pump Infusion Set Wear-Time During Treatment with Fast-Acting Insulin Aspart: A Post Hoc Analysis of Onset 5. Diabetes Technol Ther. 2022 Jan;24(1):10-17. doi: 10.1089/dia.2021.0199. Epub 2021 Dec 14. PubMed 34524005 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Jun 2017, 11 months.

Results were first posted in Jul 2018, 1 year 1 month after primary completion.

Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's 11 months is below that.

Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2016
First posted
Jul 7, 2016
StartActual
Jul 6, 2016
Primary completionActual
Jun 20, 2017
CompletionActual
Jul 21, 2017
Results first posted
Jul 24, 2018
Last update
Nov 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02825251
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jul 7, 2016
Start date
Jul 6, 2016
Primary completion
Jun 20, 2017
Completion
Jul 21, 2017
Results posted
Jul 24, 2018
Last update
Nov 21, 2019

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Aspart

Start the discussion